Clinical-Psychological Characteristics and Clonazepam Outcomes in Burning Mouth Syndrome: A Systematic Review Based on the SWiM Approach.
Cristóbal L Aravena-Ávila, Javiera F Santander-Sandoval, César Rivera
✦ AI-curated · Sources linked
In 30 seconds
This systematic review examined the clinical and psychological characteristics of patients with Burning Mouth Syndrome (BMS) and the outcomes of clonazepam treatment. Analyzing 20 studies with 1042 patients, it found that topical clonazepam led to a ≥ 30% reduction in pain in 9 of 11 studies, suggesting a more consistent symptom improvement compared to systemic administration.
Key findings
- Topical clonazepam achieved a ≥ 30% reduction in pain in 9 of 11 studies.
- A ≥ 50% reduction in pain was reported in 5 of 11 studies using topical clonazepam.
- Patients exhibited high rates of anxiety and depression alongside systemic comorbidities.
Why it matters
Understanding the clinical-psychological characteristics of BMS patients can inform treatment decisions. The variability in clonazepam outcomes highlights the need for tailored approaches in managing this complex condition.
What to keep in mind
The studies included showed substantial heterogeneity in diagnostic criteria, design, dosage, and treatment duration.